Temocillin

Summary

Temocillin (CHEMBL1276310) is a phase-3 clinical-stage small molecule (ATC J01CA17); indicated across 3 conditions including urinary tract infection and bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01CA17
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 414.5 Da · C16H18N2O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1276310
Name	Temocillin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	171758
ChEBI	CHEBI:51817
ATC	J01CA17
Molecular formula	C16H18N2O7S2
Molecular weight	414.5
InChIKey	BVCKFLJARNKCSS-DWPRYXJFSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@](C2=O)(NC(=O)C(C3=CSC=C3)C(=O)O)OC)C(=O)O)C

IUPAC name: (2S,5R,6S)-6-[(2-carboxy-2-thiophen-3-ylacetyl)amino]-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin compound having a 6α-methoxy and 6β-[2-carboxy(thiophen-3-yl)acetamido side-groups.

Also known as: BRL 17421 FREE ACID, BRL 17421 [AS SODIUM], BRL-17421, BRL-17421 FREE ACID, Temocilina, Temocillin, Temocilline, TEMOCILLIN

Patent coverage: 2,365 distinct patent families (9,523 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	3	MONDO:0100338	EFO:0003103
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
bacterial infectious disease with sepsis	3	MONDO:0005229	EFO:0003033

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01543347	PHASE4	WITHDRAWN	Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae
NCT02260102	PHASE4	UNKNOWN	Temocillin Pharmacokinetics in Paediatrics
NCT02681263	PHASE4	UNKNOWN	Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
NCT02959957	PHASE4	COMPLETED	Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
NCT03543436	PHASE3	COMPLETED	Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
NCT04478721	PHASE3	COMPLETED	Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
NCT03557840	Not specified	UNKNOWN	Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
NCT05413772	Not specified	COMPLETED	Temocillin in ESBL-Enterobacteriaceae Infections

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).